title: Evaluation of IgG concentration and IgG subisotypes in foals with complete or partial failure of passive transfer after administration of intravenous serum or plasma.
abstract: The purpose of this study was to evaluate the ability of an equine plasma product i.v. and a concentrated serum product i.v. to deliver antibodies to 46 foals with failure of passive transfer (FPT). Treatment of FPT was as per manufacturers recommendations, using plasma (950 ml/unit) or a concentrated serum product (250 ml/unit). Significant variables affecting the 3 day post-transfusion serum immunoglobulin G (IgG) concentration of foals included body weight, pretransfusion IgG concentration, number of product units transfused, foaling season and product administered. Plasma treatment had a greater increase in post-transfusion serum IgG concentrations compared to the serum product treatment mainly because plasma contained approximately twice the amount of IgG per unit as the serum product. The change in equine influenza virus and tetanus toxoid-specific IgGa, IgGb, and IgG(T) titres was measured in foals from pretransfusion to 3 days post-transfusion. For each gram of IgG transfused, the change in antigen-specific IgG subisotypes were similar for both treatment groups. The results of this study suggest that similar foal serum IgG concentrations can be achieved 3 days post-transfusion by administering 1 unit of plasma or 2-3 units of serum product.
authors.affiliation: Department of Health Management, Atlantic Veterinary College, Charlottetown, Prince Edward Island, Canada.
authors.forename: J T
authors.initials: JT
authors.lastname: McClure
authors.forename: J L
authors.initials: JL
authors.lastname: DeLuca
authors.forename: D P
authors.initials: DP
authors.lastname: Lunn
authors.forename: J
authors.initials: J
authors.lastname: Miller
mesh_terms: D000818:Animals; D000831:Animals, Newborn / Q000097:blood / Q000276:immunology*; D006734:Horse Diseases / Q000276:immunology; D006736:Horses / Q000097:blood / Q000276:immunology*; D007112:Immunity, Maternally-Acquired / Q000276:immunology*; D007116:Immunization, Passive / Q000379:methods / Q000662:veterinary*; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000097:blood*; D007132:Immunoglobulin Isotypes / Q000008:administration & dosage / Q000097:blood; D007252:Influenza Vaccines / Q000008:administration & dosage; D007275:Injections, Intravenous / Q000662:veterinary; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000662:veterinary; D013742:Tetanus / Q000276:immunology / Q000662:veterinary; D013745:Tetanus Toxoid / Q000008:administration & dosage
chemical_list: D007074:Immunoglobulin G; D007132:Immunoglobulin Isotypes; D007252:Influenza Vaccines; D013745:Tetanus Toxoid